1. LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. (23rd October 2018) Authors: Cappuzzo, F; McCleod, M; Hussein, M; Morabito, A; Rittmeyer, A; Conter, H J; Kopp, H-G; Daniel, D; McCune, S; Mekhail, T; Zer, A; Reinmuth, N; Sadiq, A; Archer, V; Ochi Lohmann, T; Wang, L; Kowanetz, M; Lin, W; Sandler, A; West, H Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA1IMpower133: Primary efficacy and safety + CNS-related adverse events in a phase I/III study of first-line (1L) atezolizumab + carboplatin + etoposide in extensive-stage SCLC (ES-SCLC). (25th November 2018) Authors: Mok, T S K; Reck, M; Horn, L; Lam, S; Shames, D S; Liu, J; Kabbinavar, F; Lin, W; Sandler, A; Liu, S V Journal: Annals of oncology Issue: Volume 29(2018)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN). (23rd October 2018) Authors: Haddad, R; Wong, D J; Guo, Y; Fayette, J; Cohen, E E W; Kowgier, M; Sandler, A; Matheny, C; Kabbinavar, F; Raben, D Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗